Working to improve women’s lives by offering targeted treatment options for urological diseases.

Working to improve women’s lives by offering targeted treatment options for urological diseases.

Working to improve women’s lives by offering targeted treatment options for urological diseases.

Tell me more

Overactive Bladder (OAB) hugely impacts the quality of life in women

Millions of women suffer in silence from Overactive Bladder (OAB) every day. This chronic condition causes patients to have debilitating and disturbing symptoms, preventing them from leading normal lives. While there are different treatment options for OAB, most are still not guaranteed to work for most patients, and many have undesirable side effects.

20%

of female population above the age of 40 is diagnosed with Overactive Bladder (OAB)

20%

of female population above the age of 40 is diagnosed with Overactive Bladder (OAB)

Overactive Bladder (OAB) hugely impacts the quality of life in women.

Millions of women suffer in silence from Overactive Bladder (OAB) every day. This chronic condition causes patients to have debilitating and disturbing symptoms, preventing them from leading normal lives. While there are different treatment options for OAB, most are still not guaranteed to work for most patients, and many have undesirable side effects.

Ovulum

Our idea to revolutionize the quality of life for OAB patients

Inura is developing the first-of-a-kind, easy-to-use urethral ovulum, which enables local delivery of oxybutynin to the urinary tract. This approach enables the medication to be released locally and avoids major side effects. It is also expected to provide patients with quick relief that can last up to 8 hours. Inura has recently completed its pre-clinical phase with promising results and plans to start with clinical trials in 2022.

The ovulum shown is for illustration purpose only.

Ovulum

Our idea to revolutionize the quality of life for OAB patients

Inura is developing the first-of-a-kind, easy-to-use urethral ovulum, which enables local delivery of oxybutynin to the urinary tract. This approach enables the medication to be released locally and avoids major side effects. It is also expected to provide patients with quick relief that can last up to 8 hours. Inura has recently completed its pre-clinical phase with promising results and plans to start with clinical trials in 2022.

The ovulum shown is for illustration purpose only.

Ovulum

The ovulum shown is for illustration purpose only.

Our idea to revolutionize the quality of life for OAB patients

Inura is developing the first-of-a-kind, easy-to-use urethral ovulum, which enables local delivery of oxybutynin to the urinary tract. This approach enables the medication to be released locally and avoids major side effects. It is also expected to provide patients with quick relief that can last up to 8 hours. Inura has recently completed its pre-clinical phase with promising results and plans to start with clinical trials in 2022.

More about ovulum

What the market says…

As we are moving towards clinical trials, we started a survey and asked Urologists and Gynecologists for their expert opinion. The following are the most important results of the survey:

90%

of volunteers gave positive feedback after ovulum insertion.

84%

of physicians want a new approach.

48%

of physicians would prescribe urethal ovulum.

Urologist (survey respondent):

“A new option for a lot of women after unsuccessful treatment…”

What the market says…

As we are moving towards clinical trials, we started a survey and asked Urologists and Gynecologists for their expert opinion. The following are the most important results of the survey:

90%

of volunteers gave positive feedback after ovulum insertion.

84%

of physicians want a new approach.

48%

of physicians would prescribe urethal ovulum.

Urologist (survey respondent):

“A new option for a lot of women after unsuccessful treatment…”